Shares in Rolls-Royce have spiked after the FTSE 100 giant revealed better-than-expected interim results this morning.

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

IMDEX Limited (ASX: IMD) ("IMDEX") or the ("Company"), has acquired Norway-based Earth Science Analytics AS ("ESA") as part ...

By the end of 2025, NDAChain will be fully integrated into the National Data Center and gradually expanded to local ...